Recently,
growing attention has been paid to the changes of brain
biomarkers following the epilepsy. However, establishing specific
epilepsy-related biomarkers has been impeded due to contradictory
findings. This study systematically reviewed the evidence on brain
biomarkers in epilepsy and determined reliable biomarkers in epileptic
patients. A comprehensive systematic search of online databases was
performed to find eligible studies up to August 2019. The quality
of studies methodologically was assessed using the Newcastle–Ottawa
Scale score. Among the several biomarkers, S100 calcium binding protein
B (S100B) and neuron specific enolase (NSE) have been qualified for
meta-analysis of the association between epilepsy and the brain biomarkers.
Inverse-variance weights method was used to calculate pooled standardized
mean difference (SMD) estimate with 95% CI, and random effects meta-analysis
was conducted taking into account conceptual heterogeneity. Sensitivity
analysis and publication bias assessment was performed using Stata.
Of 29 studies that were qualified for further analysis, only 22 studies
were eligible to quantify by meta-analysis. Significant increase of
serum S100B levels (SMD = 0.80; 95% CI 0.18 to 1.42) but not NSE (SMD
= 0.45; 95% CI −0.09 to 1.00) has been found in epileptic patients
compared with healthy controls. Subgroup meta-analysis by age demonstrated
that S100B could be found in pediatric (SMD = 1.15; 95% CI 0.03 to
2.27) not adult patients (SMD = 0.43; 95% CI −0.12 to 0.98).
Findings of this meta-analysis indicate that serum level of S100B
is significantly increased in epileptic patients, suggesting the elevation
and release of the brain biomarkers from brain to blood following
epileptic seizures.